Clene (CLNN) has provided an announcement.
A recent press release from the Company has revealed promising results for CNM-Au8 as a potential therapy for MS, showcasing its capabilities for repair and remyelination. These findings were presented at the prestigious Emerging Science Session of the 2024 American Academy of Neurology Annual Meeting, signaling a significant advancement in the treatment of multiple sclerosis.
For a thorough assessment of CLNN stock, go to TipRanks’ Stock Analysis page.
